Acurx Pharmaceuticals, Inc. develops small-molecule antibiotics for difficult-to-treat bacterial infections through a Gram-positive selective spectrum approach targeting DNA polymerase IIIC. Its pipeline includes ibezapolstat for Clostridioides difficile infection and additional DNA pol IIIC inhibitor candidates directed at Gram-positive pathogens such as MRSA, VRE, drug-resistant Streptococcus pneumoniae and B. anthracis.
Recurring ACXP news covers antibiotic development updates, microbiome data, scientific conference presentations, intellectual property for DNA pol IIIC inhibitors, financial results, registered offerings, warrant activity and investor-presentation announcements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) recently presented key findings at ECCMID 2023 in Copenhagen regarding its novel antibiotic ibezapolstat. Research showcased ibezapolstat’s unique action against C. difficile infections, demonstrating efficacy against resistant strains. The presentation highlighted positive outcomes from Phase 2a trials, where ibezapolstat achieved 100% clinical cure rates without recurrence. Additionally, updates on the company's preclinical antibiotic program targeting systemic gram-positive infections were provided. Ibezapolstat has already received FDA QIDP and Fast-Track Designation, indicating its potential as a significant treatment for bacterial infections. Acurx is currently enrolling patients for a Phase 2b clinical trial for C. difficile infection.